Jaguar Health (JAGX) investor relations material

Company overview and business model

• Develops proprietary prescription drugs from plant sources for complex gastrointestinal diseases in humans and animals, with a focus on orphan and rare GI conditions through subsidiaries and joint ventures.

• Key products include FDA-approved Mytesi for HIV/AIDS-related diarrhea and Canalevia-CA1 for chemotherapy-induced diarrhea in dogs; both use crofelemer as the active ingredient.

• Expanding crofelemer's indications to address cancer therapy-related diarrhea, microvillus inclusion disease (MVID), and short bowel syndrome with intestinal failure (SBS-IF).

• Holds global unencumbered rights for crofelemer and is pursuing regulatory approvals and orphan drug designations in the US and EU.

Financial performance and metrics

• Received $16 million non-dilutive capital in January 2026 from a licensing agreement, with an additional $2 million pending and up to $20 million in potential milestone payments.

• Entered a $40 million equity line of credit in June 2026, allowing for flexible capital raises based on market conditions.

• Closed a $2 million Series P Preferred Stock financing in June 2026, with 240 shares issued.

Use of proceeds and capital allocation

• Proceeds from the Series P Preferred Stock financing are intended for general corporate purposes, subject to restrictions in the purchase agreements.

• Will not receive proceeds from the resale of shares by selling stockholders; all registration costs are borne by the company.